The Trump administration’s 11th hour attempt to bring down high prescription drug costs succeeded in drawing swift condemnation from health care stakeholders who frequently find themselves at odds. The finalization last month of two rules intended to ease the financial burden on patients was characterized as a victory for consumers by the president.
“This is a very big announcement — the biggest ever, concerning drugs and drug pricing,” Trump said. He went on to tout the “most favored nation” rule, asserting that it “will transform the way the U.S. government pays for drugs to end global freeloading on the backs of American citizens and American patients. Until now, Americans have often been charged more than twice as much for the exact same drug as other medically advanced countries.” Read more here.
(Source: Jeffrey Woldt; Chain Drug Review; December 7, 2020)